^
Association details:
| Biomarker: | CTNNB1 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | VIC-1911 (Aurora kinase A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, ß-Catenin, and TRK pathways
Published date:
01/06/2021
Excerpt:
In a xenograft model of human lung cancer cells harboring MYC amplification and CTNNB1 mutation, TAS-119 showed a strong antitumor activity at well-tolerated doses.
DOI:
10.1007/s10637-020-01019-9
